MECOM amplified endometrial cancer, a novel subset of copy number high tumors associated with poor prognosis
ECs with <i>MECOM</i> amplification are associated with poor clinical outcomes, even in the absence of <i>CCNE1</i> or <i>ERBB2</i> amplification. The current literature is limited, and further studies are warranted to determine the role of <i>MECOM</i> amplification in ECs.
Authors
- Shariska P Harrington
- Jamie Nadine Bakkum-Gamez (ORCID: https://orcid.org/0000-0001-7018-8625)
- Alexandre Gaspar‐Maia (ORCID: https://orcid.org/0000-0001-8528-5575)
- Aminah Jatoi (ORCID: https://orcid.org/0000-0002-1081-189X)
- William A. Cliby (ORCID: https://orcid.org/0000-0002-7565-9884)
- S. John Weroha (ORCID: https://orcid.org/0000-0002-7130-7259)
- Andrea Mariani (ORCID: https://orcid.org/0000-0003-2624-1200)
- Dineo Khabele (ORCID: https://orcid.org/0000-0002-3972-743X)
- J. Romaní
Institutions
- Gynecologic Oncology Group (US)
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.gore.2025.101993
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00